Breast Cancer Clinical Trials in Atlanta

Showing 141-160 of 571 trials

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

NCT04647487

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.

Breast Cancer

Eli Lilly and Company87 participantsStarted Apr 2021

Atlanta, Georgia, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +16 more locations

RECRUITINGPhase 1< 1 mile

A Study of XMT-1660 in Participants With Solid Tumors

NCT05377996

A Study of XMT-1660 in Solid Tumors

Triple Negative Breast CancerBreast CancerEndometrial Cancer+4 more

Mersana Therapeutics319 participantsStarted Aug 2022

Phoenix, Arizona, United States • Orange, California, United States • San Francisco, California, United States +23 more locations

A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

A Study of XMT-1660 in Participants With Solid Tumors

Breast Cancer Trials in Other Cities

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

A Study of PF-06873600 in People With Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

MARGetuximab Or Trastuzumab (MARGOT)

Other Conditions in Atlanta